SCHEMBL9949560

SCHEMBL9949560

COC(=O)c1cccc(-c2cnn3ccnc3c2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 2/20 0.55
GABRG2 P18507 1/20 0.50
GABRB3 P28472 1/20 0.50
GABRA5 P31644 1/20 0.50
GABRA3 P34903 1/20 0.50
NEK1 Q96PY6 5/20 0.48
ABL1 P00519 2/20 0.47
AURKA O14965 1/20 0.47
DAPK3 O43293 1/20 0.47
JAK2 O60674 1/20 0.47
MAP4K4 O95819 1/20 0.47
NTRK1 P04629 1/20 0.47
CSF1R P07333 1/20 0.47
RET P07949 1/20 0.47
FGFR1 P11362 1/20 0.47
PRKACA P17612 1/20 0.47
KDR P35968 1/20 0.47
MAP2K2 P36507 1/20 0.47
MAPK8 P45983 1/20 0.47
GSK3A P49840 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9950069 0.86 ALDH1A1 (0.45) CDK8ABL1AURKADAPK3JAK2
SCHEMBL837898 0.85 CDK8 (0.55) CDK8ABL1AURKADAPK3JAK2
SCHEMBL24542418 0.80 STING1 (0.47) CYP19A1CYP11B1CYP11B2CA12CA1
SCHEMBL15981029 0.78 CDK8 (0.52) CDK8GABRG2GABRB3GABRA5GABRA3
SCHEMBL9949714 0.77 CDK8 (0.51) CDK8GABRG2GABRB3GABRA5GABRA3
SCHEMBL67941 0.75 CA12 (0.68) CDK8GABRG2GABRB3GABRA5GABRA3
SCHEMBL23165344 0.74 GABRG2 (0.53) CDK8GABRG2GABRB3GABRA5GABRA3
SCHEMBL27715902 0.73 CA12 (0.71) CDK8GABRG2GABRB3GABRA5GABRA3
SCHEMBL5558179 0.72 CDK8 (0.56) CDK8GABRG2GABRB3GABRA5GABRA3
SCHEMBL1399775 0.72 CYP19A1 (0.74) CDK8GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10813930-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2020-10-27 US disclosed
US-10813930-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2020-10-27 US disclosed
US-20190240220-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2019-08-08 US disclosed
US-20190240220-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2019-08-08 US disclosed
US-20170165263-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2017-06-15 US disclosed
US-20170165263-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2017-06-15 US disclosed
US-20170165263-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2017-06-15 US disclosed
US-9533954-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2017-01-03 US disclosed
US-9533954-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2017-01-03 US disclosed
US-20140243308-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION (US) 2014-08-28 US disclosed
US-20140243308-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION (US) 2014-08-28 US disclosed
US-20140243308-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION (US) 2014-08-28 US disclosed
US-8754114-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2014-06-17 US disclosed
US-8754114-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2014-06-17 US disclosed
US-8754114-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2014-06-17 US disclosed
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 US disclosed
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 US disclosed
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 US disclosed
WO-2012088266-A2 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190240220-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 CDK8 50/4885GABRG2 465/4885GABRB3 701/4885
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 CDK8 50/4885GABRG2 465/4885GABRB3 701/4885
US-10813930-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 FGFR3, FGFR4, FGFR2 CDK8 50/4885GABRG2 465/4885GABRB3 701/4885
US-20170165263-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 CDK8 50/4885GABRG2 465/4885GABRB3 701/4885
US-20140243308-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 CDK8 50/4885GABRG2 465/4885GABRB3 701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.